Xaciato is owned by Dare.
Xaciato contains Clindamycin Phosphate.
Xaciato has a total of 1 drug patent out of which 0 drug patents have expired.
Xaciato was authorised for market use on 07 December, 2021.
Xaciato is available in gel;vaginal dosage forms.
Xaciato can be used as method of treating bacterial vaginosis by single dose administration of a clindamycin pharmaceutical gel formulation.
The generics of Xaciato are possible to be released after 22 September, 2036.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11129896||DARE||Topical formulations and treatments|| |
(13 years from now)
|New Product (NP)||Dec 7, 2024|
|Generating Antibiotic Incentives Now (GAIN)||Dec 7, 2029|
Market Authorisation Date: 07 December, 2021
Treatment: Method of treating bacterial vaginosis by single dose administration of a clindamycin pharmaceutical gel formulation
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic